Licofelone, a dual cyclooxygenase/5-lipoxygenase inhibitor, reverses endotoxin-induced impaired atrial chronotropic responsiveness to cholinergic stimulation in rats
Copyright © 2020 Elsevier B.V. All rights reserved..
Evidence show that endotoxemia is linked with tachycardia. The exact mechanism of tachycardia is not well-understood, but it seems that impaired cardiac chronotropic responsiveness to cholinergic stimulation plays a role in this phenomenon. The aim of this experiment was to study the effect of licofelone as a dual cyclooxygenase (COX)/5-lipoxygenase (5-LOX) inhibitor in modulation of atrial chronotropic hyporesponsiveness to cholinergic stimulation in endotoxemic rats, compared with hydrocortisone and indomethacin in in vitro and in vivo studies. Rats were injected by either of lipopolysaccharide (LPS) or saline. The isolated atria were incubated with licofelone, hydrocortisone, or indomethacin in an organ bath set up. In a separate experiment, rats were injected with licofelone, hydrocortisone, or indomethacin prior to isolation of the atria. Then, in both experiments, chronotropic responsiveness to cumulative concentrations of carbacholine in organ bath was recorded. LPS injection decreased the chronotropic responsiveness to cholinergic stimulation in both in vitro and in vivo experiments, significantly (P < 0.0001), while either incubation of isolated atria with licofelone (a dual COX/5-LOX inhibitor) or injection of licofelone to animals could reverse it, completely (P < 0.01). Hydrocortisone (phospholipase A2 and COX-2 inhibitor) in vitro and in vivo (P < 0.001, P < 0.05, respectively) as well as indomethacin (COX inhibitor) in vitro and in vivo (P < 0.05, P < 0.01, respectively) exerted some lesser effects. Our data revealed that in endotoxemic rats, chronotropic hyporesponsiveness to cholinergic stimulation was modulated by the dual COX/5-LOX inhibitor licofelone, and this effect is comparable with hydrocortisone and indomethacin.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:887 |
---|---|
Enthalten in: |
European journal of pharmacology - 887(2020) vom: 15. Nov., Seite 173569 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Nikoui, Vahid [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 14.05.2021 Date Revised 14.05.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1016/j.ejphar.2020.173569 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM315209739 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM315209739 | ||
003 | DE-627 | ||
005 | 20231225154420.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ejphar.2020.173569 |2 doi | |
028 | 5 | 2 | |a pubmed24n1050.xml |
035 | |a (DE-627)NLM315209739 | ||
035 | |a (NLM)32949599 | ||
035 | |a (PII)S0014-2999(20)30661-0 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Nikoui, Vahid |e verfasserin |4 aut | |
245 | 1 | 0 | |a Licofelone, a dual cyclooxygenase/5-lipoxygenase inhibitor, reverses endotoxin-induced impaired atrial chronotropic responsiveness to cholinergic stimulation in rats |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 14.05.2021 | ||
500 | |a Date Revised 14.05.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
520 | |a Evidence show that endotoxemia is linked with tachycardia. The exact mechanism of tachycardia is not well-understood, but it seems that impaired cardiac chronotropic responsiveness to cholinergic stimulation plays a role in this phenomenon. The aim of this experiment was to study the effect of licofelone as a dual cyclooxygenase (COX)/5-lipoxygenase (5-LOX) inhibitor in modulation of atrial chronotropic hyporesponsiveness to cholinergic stimulation in endotoxemic rats, compared with hydrocortisone and indomethacin in in vitro and in vivo studies. Rats were injected by either of lipopolysaccharide (LPS) or saline. The isolated atria were incubated with licofelone, hydrocortisone, or indomethacin in an organ bath set up. In a separate experiment, rats were injected with licofelone, hydrocortisone, or indomethacin prior to isolation of the atria. Then, in both experiments, chronotropic responsiveness to cumulative concentrations of carbacholine in organ bath was recorded. LPS injection decreased the chronotropic responsiveness to cholinergic stimulation in both in vitro and in vivo experiments, significantly (P < 0.0001), while either incubation of isolated atria with licofelone (a dual COX/5-LOX inhibitor) or injection of licofelone to animals could reverse it, completely (P < 0.01). Hydrocortisone (phospholipase A2 and COX-2 inhibitor) in vitro and in vivo (P < 0.001, P < 0.05, respectively) as well as indomethacin (COX inhibitor) in vitro and in vivo (P < 0.05, P < 0.01, respectively) exerted some lesser effects. Our data revealed that in endotoxemic rats, chronotropic hyporesponsiveness to cholinergic stimulation was modulated by the dual COX/5-LOX inhibitor licofelone, and this effect is comparable with hydrocortisone and indomethacin | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Chronotropic response | |
650 | 4 | |a Cyclooxygenase | |
650 | 4 | |a Endotoxin | |
650 | 4 | |a Licofelone | |
650 | 4 | |a Lipoxygenase | |
650 | 4 | |a Systemic inflammation | |
650 | 7 | |a Anti-Inflammatory Agents |2 NLM | |
650 | 7 | |a Cholinergic Agents |2 NLM | |
650 | 7 | |a Cyclooxygenase Inhibitors |2 NLM | |
650 | 7 | |a Endotoxins |2 NLM | |
650 | 7 | |a Lipopolysaccharides |2 NLM | |
650 | 7 | |a Lipoxygenase Inhibitors |2 NLM | |
650 | 7 | |a Pyrroles |2 NLM | |
650 | 7 | |a Carbachol |2 NLM | |
650 | 7 | |a 8Y164V895Y |2 NLM | |
650 | 7 | |a Arachidonate 5-Lipoxygenase |2 NLM | |
650 | 7 | |a EC 1.13.11.34 |2 NLM | |
650 | 7 | |a licofelone |2 NLM | |
650 | 7 | |a P5T6BYS22Y |2 NLM | |
650 | 7 | |a Hydrocortisone |2 NLM | |
650 | 7 | |a WI4X0X7BPJ |2 NLM | |
650 | 7 | |a Indomethacin |2 NLM | |
650 | 7 | |a XXE1CET956 |2 NLM | |
700 | 1 | |a Mehrzadi, Saeed |e verfasserin |4 aut | |
700 | 1 | |a Khan, Muhammad Imran |e verfasserin |4 aut | |
700 | 1 | |a Aman, Waqar |e verfasserin |4 aut | |
700 | 1 | |a Ostadhadi, Sattar |e verfasserin |4 aut | |
700 | 1 | |a Dehpour, Ahmad Reza |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t European journal of pharmacology |d 1967 |g 887(2020) vom: 15. Nov., Seite 173569 |w (DE-627)NLM000029769 |x 1879-0712 |7 nnns |
773 | 1 | 8 | |g volume:887 |g year:2020 |g day:15 |g month:11 |g pages:173569 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ejphar.2020.173569 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 887 |j 2020 |b 15 |c 11 |h 173569 |